导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.20% | 1133/4773 |
| 近一周 | -0.72% | 1215/5465 |
| 近一月 | -1.89% | 1363/5421 |
| 近一季 | -11.21% | 3886/5231 |
| 近半年 | -4.57% | 2867/4920 |
| 近一年 | 9.97% | 1145/4394 |
| 近两年 | 91.90% | 703/2954 |
| 近三年 | 39.41% | 782/2253 |
| 成立以来 | 204.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.06% 597/4961 |
18.61% 1362/5312 |
- - |
- - |
| 2025 | 37.61% 892/4813 |
5.52% 768/3635 |
5.49% 581/4076 |
19.86% 2085/4524 |
3.15% 736/4813 |
| 2024 | 0.24% 2082/3463 |
-8.97% 2255/2808 |
-6.09% 1851/3014 |
12.81% 2287/3129 |
3.93% 751/3463 |
| 2023 | -6.41% 839/2656 |
11.65% 327/2280 |
-4.42% 1166/2385 |
-8.28% 1688/2515 |
-4.38% 995/2655 |
| 2022 | -8.65% 157/2207 |
-9.41% 326/1919 |
5.87% 813/2016 |
-8.51% 207/2113 |
4.11% 588/2208 |
| 2021 | 30.34% 68/1822 |
-3.17% 772/1255 |
15.18% 235/1330 |
10.34% 124/1466 |
5.92% 255/1822 |
| 2020 | 33.51% 457/1250 |
-0.01% 174/1028 |
18.79% 324/1067 |
7.03% 806/1164 |
5.02% 815/1184 |
| 2019 | 40.33% 256/1092 |
31.52% 199/739 |
-6.93% 530/788 |
4.30% 205/850 |
9.92% 177/918 |
| 2018 | - - |
- - |
-0.03% 43/631 |
0.35% 154/660 |
-6.10% 42/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 万家中证1000指数增强A VS. 长安沪深300非周期A(740101) |